- Investor's Business Daily•3 hours ago
Alnylam's fitusiran will pull in $989 million in 2025, but won't launch until 2020 amid competition with Biogen spinoff Bioverativ.
- American City Business Journals•2 days ago
The CEO of Alnylam Pharmaceuticals saw his compensation drop precipitously in 2016 as the Cambridge biotech lost about half of its market value, according to a federal filing. John Maraganore received about $1.7 million in total compensation in 2016, down from nearly $8.3 million in 2015, a decrease of nearly 80 percent, according to the filing on Friday. The filing shows that Maraganore realized nearly $4.9 million in value by exercising options in 2016.
- Zacks•2 days ago
Alnylam Pharmaceuticals, Inc. (ALNY) and its partner The Medicines Company (MDCO) announced positive final results from the phase II study, ORION-1, on their experimental PCSK9 inhibitor, inclisiran.
ALNY : Summary for Alnylam Pharmaceuticals, Inc. - Yahoo Finance
Alnylam Pharmaceuticals, Inc. (ALNY)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
|Bid||52.00 x 100|
|Ask||53.80 x 2000|
|Day's Range||52.01 - 54.60|
|52 Week Range||31.38 - 80.11|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||-11.11|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|